Johnson Pharmacare Limited has announced significant changes to its Board of Directors with the resignation of two key members effective April 17, 2026. The pharmaceutical company disclosed these developments in compliance with regulatory requirements under SEBI listing obligations.

Board Meeting and Resignations Approved

The company's Board of Directors convened on April 17, 2026, from 5:15 p.m. to 5:45 p.m. to address the resignation matters. During this meeting, the Board formally approved the resignations of both directors and ensured compliance with all necessary regulatory disclosures.

Director Resignation Details

The resignations involve two directors holding different positions within the company structure:

Both directors cited personal and unavoidable reasons for their resignations. The company has confirmed receipt of written confirmations from both departing directors stating that no other material reasons exist beyond those provided in their resignation letters.

Regulatory Compliance and Disclosures

Johnson Pharmacare Limited made the announcements pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive brief profiles of both resigning directors as required by regulatory guidelines.

Additional Directorships

Both Mr. Rajender Parsad and Mr. Umesh Kumar hold professional category directorships in Space Incubatrics Technologies Limited. This information was disclosed as part of the mandatory requirements for director resignation announcements.

Company Information

Johnson Pharmacare Limited operates from its registered office located at Office No. 4-D, Fourth Floor Vardan Tower, Lakhudi Circle, Near Sardar Patel Stadium, Navrangpura, Ahmedabad, Gujarat. The company is incorporated under CIN: L51100GJ1994PLC022388 and maintains its listing compliance through regular Board meetings and timely regulatory disclosures.

The resignations represent routine corporate governance changes, with both directors stepping down for personal reasons while ensuring proper transition and compliance with all applicable regulations.

Johnson Pharmacare Limited has filed its quarterly compliance certificate with BSE Limited for the quarter ended 31st March, 2026, fulfilling regulatory obligations under SEBI depositories regulations. The pharmaceutical company, formerly known as Sun and Shine Worldwide Limited, submitted the mandatory documentation on 13.04.2026.

Regulatory Compliance Filing

The company submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for Q4FY26. This regulation requires listed companies to provide quarterly certificates regarding the dematerialization of physical share certificates.

Certificate Confirmation

Satellite Corporate Services Private Limited, serving as the company's Registrar & Share Transfer Agent, issued the compliance certificate dated 06.04.2026. The certificate confirms that no physical share certificates were received for dematerialization during the quarter ended 31st March, 2026.

The registrar confirmed compliance with standard verification procedures, stating that securities comprised in certificates are listed on stock exchanges and that proper verification and cancellation processes are followed when physical certificates are processed for dematerialization.

Company Information

The submission was signed by Rajendra Prasad, Additional Director of Johnson Pharmacare Limited, ensuring proper authorization of the regulatory filing. This quarterly compliance demonstrates the company's adherence to SEBI regulations governing depositories and participants in the Indian securities market.